In contrast, previous Mendelian randomization studies showed that IgD+CD24+ B cells are risk factors for glioblastoma (45), suggesting differences across tumor types and necessitating further experimental research to elucidate the roles of various immune cell phenotypes in CRC development and progression. Here, CD24 is linked to glioblastoma.